Research ArticleOriginal Article
Open Access

The expression and significance of long non-coding RNA ITGB2-AS1 in renal clear cell carcinoma

Wei Zhou, Zhi-Gang Liu and Lian-Qu Wang
Saudi Medical Journal January 2023, 44 (1) 19-28; DOI: https://doi.org/10.15537/smj.2023.44.1.20220533

Article Figures & Data

Figures

  • Figure 1
    Figure 1

    - The expression of ITGB2-AS1 in kidney renal clear cell carcinoma (KIRC) and correlation with prognosis. A) The expression of ITGB2-AS1 in KIRC analyzed by gene expression profiling interactive analysis (GEPIA) database. B) The expression of ITGB2-AS1 in KIRC and adjacent tissues from 45 patients with KIRC was detected by real-time quantitative polymerase chain reaction. C) Survival analysis results of 515 KIRC patients retrieved from GEPIA database. D) The relationship between ITGB2-AS1 expression and overall survival of 45 KIRC patients was analyzed by Kaplan-Meier. *P-value of <0.05.

  • Figure 2
    Figure 2

    - The effect of ITGB2-AS1 on the proliferation and apoptosis of kidney renal clear cell carcinoma (KIRC) cells. A) The expression of ITGB2-AS1 in human kidney-2 (HK-2) and KIRC cell lines (A498, 786-O, ACHN, and Caki-1), *p<0.05, versus HK-2 cell. B) The expression of ITGB2-AS1 in Caki-1 cell after transfected with siRNA-ITGB2-AS1, *p<0.05, versus the siRNA-NC group. C) The expression of ITGB2-AS1 in ACHN cell after transfected with pcDNA3.1-ITGB2-AS1, *p<0.05, versus the siRNA-NC group. D) The proliferation activity of Caki-1 cell after down-regulation of ITGB2-AS1. E) The proliferation activity of ACHN cell after up-regulation of ITGB2-AS1, *p<0.05, versus the Vector group. F) The apoptosis rate of Caki-1 cell after down-regulation of ITGB2-AS1, *p<0.05, versus the siRNA-NC group. G) The apoposis rate of ACHN cell after up-regulation of ITGB2-AS1, *p<0.05, versus the Vector group.

  • Figure 3
    Figure 3

    - The effect of ITGB2-AS1 on invasion and migration abilities of kidney renal clear cell carcinoma (KIRC) cells. A) The invasion ability of Caki-1 cell after down-regulation of ITGB2-AS1, scale bar: 50 µm, *p<0.05, versus the siRNA-NC group. B) The invasion ability of ACHN cell after up-regulation of ITGB2-AS1, scale bar: 50 µm, *p<0.05, versus the Vector group. C) The migration ability of Caki-1 cell after down-regulation of ITGB2-AS1, scale bar: 100 µm, *p<0.05, versus the siRNA-NC group. D) The migration ability of ACHN cell after up-regulation of ITGB2-AS1, scale bar: 100 µm, *p<0.05, versus the Vector group.

  • Figure 4
    Figure 4

    - ITGB2-AS1 targeted regulate miR-338-3p/epidermal growth factor receptor (EGFR) axis in kidney renal clear cell carcinoma (KIRC). A) The binding site of miR338-3p in the ITGB2-AS1 was predicted by LncBase Predicted v.2 and verified by dual luciferase reporter gene assay, *p<0.05, versus the miR-NC group. B) The binding site of miR-338-3p in 3’UTR of EGFR was predicted by Starbase 3.0 and verified by dual luciferase reporter gene assay, *p<0.05, versus the miR-NC group. C&D) The direct correlation between ITGB2-AS1 and miR-338-3p or miR-338-3p and EGFR, both in Caki and ACHN cells, were confirmed by RNA pull-down assay, *p<0.05, versus the Bio-NC group. E) The expression of miR-338-3p both in Caki and ACHN cells after down-regulation or up-regulation of ITGB2-AS1, *p<0.05, versus the siRNA-NC or Vector groups. F) The expression of EGFR protein both in Caki and ACHN cells after down-regulation or up-regulation of ITGB2-AS1, *p<0.05, versus the siRNA-NC or Vector groups.

Tables

  • Table 1

    - Relationship between ITGB2-AS1 expression and clinicopathological characteristics of kidney renal clear cell carcinoma patients.

    VariablesnITGB2-AS1Comparison
    Low expression group (n=19)High expression group (n=26)
    Gender
    Male2711 (57.9)16 (61.5)χ2=0.184
    Female188 (42.1)10 (38.5)p=0.668
    Age
    <652511 (57.9)14 (53.8)χ2=0.073
    ≥65208 (42.1)12 (46.1)p=0.787
    Smoking history
    No2913 (68.4)16 (61.5)χ2==0.227
    Yes166 (31.6)10 (38.5)p=0.634
    Tumor diameter (cm)
    <5279 (47.4)18 (66.7)χ2==2.186
    ≥51810 (52.6)8 (44.4)p=0.239
    TNM stage
    I/II2715 (78.9)12 (46.1)χ2==4.919
    III/IV184 (21.0)14 (53.8)p=0.035
    Fuhrman class
    I/II2414 (73.7)10 (38.5)χ2==6.910
    III/IV215 (26.3)16 (61.5)p=0.009
    Lymph node metastasis
    No2815 (78.9)13 (50.0)χ2==3.913
    Yes174 (21.0)13 (50.0)p=0.065

    Values are presented as numbers and precentages (%). TNM: tumor node metastasis

    Back to top

    In this issue

    Print
    Download PDF
    Email Article
    Citation Tools
    Bookmark this article

    Jump to section

    Keywords